Results 211 to 220 of about 398,456 (338)

Reliability of the Probability Effect on Event-related Potentials during Repeated Testing.

open access: bronze, 1995
Sayaka Kinoshita   +4 more
openalex   +2 more sources

Effects of zolpidem and zopiclone on cognitive and attentional function in young healthy volunteers: An event‐related potential study [PDF]

open access: bronze, 2000
Toru Nakajima   +5 more
openalex   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira   +14 more
wiley   +1 more source

Task-related changes in aperiodic activity are related to visual working memory capacity independent of event-related potentials and alpha oscillations. [PDF]

open access: yesImaging Neurosci (Camb)
Virtue-Griffiths S   +7 more
europepmc   +1 more source

P01.127 Event related potentials (CNV and P300) in chronic opiate users: Preliminary results [PDF]

open access: bronze, 2000
E. Pinto   +5 more
openalex   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

open access: yesMolecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian   +10 more
wiley   +1 more source

Effects of risperidone on auditory event-related potentials in schizophrenia

open access: green, 1999
Daniel Umbricht   +6 more
openalex   +2 more sources

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy